Diagnostic Biomarkers Market Analysis

The market is segmented by product into consumable, software, and service, out of which, the consumable segment is anticipated to hold the largest share in the market during the forecast period on account of easy availability and affordable process of consumables, as compared to screening devices, and other biomarkers. On the basis of application, the market is segmented into oncology, metabolic diseases, neurological diseases, and others, out of which, the oncology segment is anticipated to attain notable growth during the forecast period, on the back of increasing cases of cancer globally, along with high mortality rate associated with cancer. As per other statistics of the WHO, cancer is the second leading cause of death globally, accounting for almost 9.6 million deaths, in the year 2018.

Our in-depth analysis of the global market includes the following segments:

Product

Consumable
Software
Service

Application

Oncology
Metabolic Disease
Neurological Disease
Others

End-Use

Hospital
Academic Research Institute
Diagnostic Center
Others

Frequently Asked Questions (FAQ)

Rising demand for early diagnosis backed by increasing prevalence of the acute and chronic disease is one of the major factors driving the market growth.

High costs of diagnostic biomarkers is one of the major factors estimated to hamper the market growth.

The market in the North America is estimated to provide most growth opportunities owing to the efficient healthcare sector, high government investment, and growing medical R&D activities.

The major players in the market are PerkinElmer Inc., Biomarker Technologies, Inc., Almac Group Limited, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Epigenomics AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., QIAGEN GmbH and others.

Diagnostic Biomarkers Market Analysis